ClinicalTrials.gg
CompletedNCT00358462Updated Aug 15, 2018Results posted

Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)

A Phase 3 interventional study of Azithromycin and Doxycycline in Urethritis, sponsored by University of Washington. Completed at 1 site in United States. Open to male participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-08-15.

Sponsored by University of Washington · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
606
Allocation
Randomized
Ages
16 Years and older
Sex
Male
01

Study summary

The purpose of this study is to find out which of 2 different antibiotics, doxycycline or azithromycin, works best against germs that may cause nongonococcal urethritis.

Study participants will include approximately 1200 men, 16 years of age or older, attending a sexually transmitted diseases clinic in Seattle, Washington with clinical signs of urethral inflammation (>=5PMNs/HPF on a Gram-stained slide prepared from urethral exudates and/or a visible urethral discharge upon examination).

Urine specimens will be collected and tested for Mycoplasma genitalium and Ureaplasmas. Each participant will receive a blinded packet of study medication. Participants will answer an enrollment questionnaire and will also receive a log to complete between visits to record information about treatment adherence, side effects, symptoms, and sexual activity. All subjects will be asked to return for evaluation 3 weeks after the initial clinic visit. Subjects who test positive for M. genitalium and/or Ureaplasmas at the initial clinic visit will also be asked to return for a third study visit, 6 weeks following the initial clinic visit. During follow-up visits, participants will answer a follow-up questionnaire and will be re-evaluated for signs of urethritis. Those who were initially positive for M. genitalium and/or Ureaplasmas will be re-tested for these organisms.

Study participants with signs and/or symptoms of urethritis or who test positive for M. genitalium or Ureaplasmas at the follow-up study visit will receive another blinded treatment packet containing the alternate medication. Those who require additional treatment at the 6-week visit will be asked to return for a fourth follow-up study visit at 9-10 weeks. Study participants who did not test positive for M. genitalium or Ureaplasmas at the initial clinic visit, but who continue to demonstrate signs and/or symptoms of infection at their single follow-up study visit will treated according to clinic standard of care (after the study clinician unblinds their randomly-assigned treatment regimen).

Read the detailed description

OBJECTIVES

The primary objective of this study is to determine the relative effectiveness of azithromycin and doxycycline in eradicating Mycoplasma genitalium and Ureaplasmas among men with nongonococcal urethritis (NGU).

Secondary objectives of this study are to:

  • determine the sensitivity of persisting organisms to azithromycin and doxycycline by performing minimum inhibitory concentration (MIC) testing
  • determine the relationship between persistence/recurrence of clinical signs and persistent/recurrent detection of M. genitalium and Ureaplasmas among men with NGU treated with azithromycin or doxycycline, measured by follow-up clinical exams and repeated assays performed on specimens collected at follow-up study visits

STUDY DESCRIPTION

1200 men with NGU, ages 16 and older, will be enrolled in a randomized double-blinded treatment trial. Urine samples, oral swabs, and urethral swabs will be obtained from each subject at the initial clinic visit. Urine specimens will be tested for M. genitalium and Ureaplasma. Study participants will be randomly assigned to receive one of two pre-packaged treatments: active doxycycline plus placebo azithromycin or active azithromycin plus placebo doxycycline. Subjects will complete a questionnaire, and will be given a simple standardized log in which they will be asked to keep track of adherence to the study drug, record solicited adverse events, note when symptoms disappear and/or reappear, and document sexual activity between study visits.

Subjects who test positive for M. genitalium or Ureaplasmas at the initial clinic visit will be asked to return for at least two follow-up study visits: at approximately 3 and 6 weeks following the initial clinic visit. During follow-up visits, participants will answer a follow-up questionnaire and will be re-evaluated for signs of urethritis and re-tested for M. genitalium and Ureaplasmas. Study participants with signs and/or symptoms of urethritis or who test positive for M. genitalium or Ureaplasmas at the follow-up study visits will receive a blinded treatment packet containing the alternate medication, or will be offered open-label moxifloxacin if the alternate treatment regimen was administered at the prior follow-up study visit. If additional treatment is administered at the 6-week follow-up study visit, a fourth study visit will be scheduled to occur approximately 9 or 10 weeks following the initial clinic visit.

Study participants who were negative for M. genitalium and Ureaplasma at enrollment will be asked to return for evaluation for a single follow-up study visit, approximately 3 weeks after the initial clinic visit. At this visit they will complete the follow-up questionnaire and provide specimens for future testing.

02

Conditions studied

  • Urethritis

Keywords

  • NGU, M genitalium, Ureaplasma, azithromycin, doxycycline
03

In context

Lead sponsor

University of Washington is the lead sponsor of 1,435 studies on the registry; 225 are open to participants now.

Of its 158 completed or terminated interventional studies of FDA-regulated products, 137 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a visible urethral discharge or greater than or equal to 5 polymorphonuclear leukocytes (PMNs) per high power field on a Gram-stained slide of a urethral swab sample
  • Possesses and is willing to disclose valid contact information for follow-up
  • English-speaking
  • Gives
  • Exhibits understanding of study procedures
  • Exhibits ability to comply with study procedures for the entire length of the study

Exclusion criteria

Exclusion Criteria:

  • Has previously participated in this study
  • Has taken antibiotics within the prior month
  • Has known allergies to tetracyclines or azithromycin
  • Is being treated with any of the following: warfarin, ergot derivatives, pimozide (Orap), propafenone (Rytmonorm, Rythmol), disopyramide (Norpace, Rythmodan), rifampin, digoxin, isotretinoin, or methotrexate
  • Has received a kidney, heart, or lung transplant.
  • Is undertaking concomitant systemic therapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
606 participants (actual)

Study arms

  • Active comparator
    Active azithromycin+placebo doxycycline

    Active azithromycin (1g) and placebo doxycycline

    Drug: Azithromycin

  • Active comparator
    Active doxycycline+placebo azithromycin

    Active doxycycline and placebo azithromycin

    Drug: Doxycycline

Interventions

  • two 500mg tablets or four 250mg tablets administered as a single dose

    Also known as: Zithromax, Zmax

  • one 100mg capsule administered twice daily for seven days

    Also known as: Doryx, Doxychel, Monodox, Oracea, Periostat, Vibra-Tabs, Vibramycin

06

What researchers measure

Primary outcomes

  1. mITT Analysis of Eradication of M. Genitalium at First Follow-up Study Visit

    Microbiologic cure of M. genitalium at first follow-up visit (defined as a negative in-house PCR test performed on urine)

    Time frame: approximately 3 weeks after initial study visit (allowable window is 2-5 weeks after initial study visit)

  2. mITT Analysis of Eradication of U. Urealyticum at First Follow-up Visit

    Microbiologic cure, defined as negative PCR for U. urealyticum (if cultured), or negative culture at first follow-up visit

    Time frame: 3 weeks (allowable window 2-5)

Secondary outcomes

  1. Clinical Cure Among Case Subjects Who Were Positive for M. Genitalium at the Initial Study Visit

    Proportion of men with M. genitalium at the initial study visit who had clinical cure, defined as \<5 PMNs/HPF (with or without urethral symptoms) on a urethral Gram stain and absence of urethral discharge at follow-up.

    Time frame: approximately 3 weeks after initial study visit (allowable window is 2-5 weeks after initial study visit)

  2. Clinical Cure Among Case Subjects Who Were Positive for Ureaplasmas at the Initial Study Visit

    Proportion of men with Ureaplasma urealyticum at the initial study visit who had clinical cure, defined as \<5 PMNs/HPF (with or without urethral symptoms) on a urethral Gram stain and absence of urethral discharge at follow-up.

    Time frame: approximately 3 weeks after initial study visit (allowable window is 2-5 weeks after initial study visit)

  3. Minimum Inhibitory Concentrations (MIC) of M. Genitalium for Azithromycin

    In vitro susceptibiities of M. genitalium to azithromycin

    Time frame: baseline

  4. Minimum Inhibitory Concentrations (MIC) of M. Genitalium for Doxycycline

    In vitro susceptibilities of M. genitalium to doxycycline

    Time frame: baseline

  5. Minimum Inhibitory Concentrations (MIC) of U. Ureaplasma Biovar 2

    In vitro susceptibilities of U. urealyticum biovar 2

    Time frame: baseline

  6. Minimum Inhibitory Concentrations (MIC) of U. Parvum

    In vitro susceptibilities of U. parvum

    Time frame: baseline

07

Results

Posted Mar 8, 2013

Participant flow

Men were recruited from a sexually transmitted diseases clinic in Seattle, Washington from January 2007 to July 2011

Participant flow — Overall Study
MilestoneActive Azithromycin + Placebo DoxycyclineActive Doxycycline + Placebo Azithromycin
Started304302
Completed245238
Not completed5964

Outcome measures

PrimarymITT Analysis of Eradication of M. Genitalium at First Follow-up Study Visit

Microbiologic cure of M. genitalium at first follow-up visit (defined as a negative in-house PCR test performed on urine)

Time frame:
approximately 3 weeks after initial study visit (allowable window is 2-5 weeks after initial study visit)
Reported as:
Number · participants
mITT Analysis of Eradication of M. Genitalium at First Follow-up Study Visit
participantsActive Azithromycin + Placebo DoxycyclineActive Doxycycline + Placebo Azithromycin
mITT Analysis of Eradication of M. Genitalium at First Follow-up Study Visit158
PrimarymITT Analysis of Eradication of U. Urealyticum at First Follow-up Visit

Microbiologic cure, defined as negative PCR for U. urealyticum (if cultured), or negative culture at first follow-up visit

Time frame:
3 weeks (allowable window 2-5)
Reported as:
Number · participants
mITT Analysis of Eradication of U. Urealyticum at First Follow-up Visit
participantsActive Azithromycin + Placebo DoxycyclineActive Doxycycline + Placebo Azithromycin
mITT Analysis of Eradication of U. Urealyticum at First Follow-up Visit3938
SecondaryClinical Cure Among Case Subjects Who Were Positive for M. Genitalium at the Initial Study Visit

Proportion of men with M. genitalium at the initial study visit who had clinical cure, defined as \<5 PMNs/HPF (with or without urethral symptoms) on a urethral Gram stain and absence of urethral discharge at follow-up.

Time frame:
approximately 3 weeks after initial study visit (allowable window is 2-5 weeks after initial study visit)
Reported as:
Number · participants
Clinical Cure Among Case Subjects Who Were Positive for M. Genitalium at the Initial Study Visit
participantsActive Azithromycin+Placebo DoxycyclineActive Doxycycline+Placebo Azithromycin
Clinical Cure Among Case Subjects Who Were Positive for M. Genitalium at the Initial Study Visit2413
SecondaryClinical Cure Among Case Subjects Who Were Positive for Ureaplasmas at the Initial Study Visit

Proportion of men with Ureaplasma urealyticum at the initial study visit who had clinical cure, defined as \<5 PMNs/HPF (with or without urethral symptoms) on a urethral Gram stain and absence of urethral discharge at follow-up.

Time frame:
approximately 3 weeks after initial study visit (allowable window is 2-5 weeks after initial study visit)
Reported as:
Number · participants
Clinical Cure Among Case Subjects Who Were Positive for Ureaplasmas at the Initial Study Visit
participantsActive Azithromycin+Placebo DoxycyclineActive Doxycycline+Placebo Azithromycin
Clinical Cure Among Case Subjects Who Were Positive for Ureaplasmas at the Initial Study Visit4340
SecondaryMinimum Inhibitory Concentrations (MIC) of M. Genitalium for Azithromycin

In vitro susceptibiities of M. genitalium to azithromycin

Time frame:
baseline
Reported as:
Count of participants · Participants
Minimum Inhibitory Concentrations (MIC) of M. Genitalium for Azithromycin
ParticipantsCultivated Isolates
MIC range <=0.001 - 0.004 ug/ml31
MIC range >8 ug/ml25
SecondaryMinimum Inhibitory Concentrations (MIC) of M. Genitalium for Doxycycline

In vitro susceptibilities of M. genitalium to doxycycline

Time frame:
baseline
Reported as:
Median · MIC (ug/mL)
Minimum Inhibitory Concentrations (MIC) of M. Genitalium for Doxycycline
MIC (ug/mL)Cultivated Isolates
Minimum Inhibitory Concentrations (MIC) of M. Genitalium for Doxycycline0.5 (0.125 to 2.0)
SecondaryMinimum Inhibitory Concentrations (MIC) of U. Ureaplasma Biovar 2

In vitro susceptibilities of U. urealyticum biovar 2

Time frame:
baseline
Reported as:
Median · MIC (ug/mL)
Minimum Inhibitory Concentrations (MIC) of U. Ureaplasma Biovar 2
MIC (ug/mL)AzithromycinDoxycyclineMoxifloxacin
Minimum Inhibitory Concentrations (MIC) of U. Ureaplasma Biovar 21.00 (0.25 to 2.00)0.5 (0.125 to 1.00)0.5 (0.25 to 1.00)
SecondaryMinimum Inhibitory Concentrations (MIC) of U. Parvum

In vitro susceptibilities of U. parvum

Time frame:
baseline
Reported as:
Median · MIC (ug/mL)
Minimum Inhibitory Concentrations (MIC) of U. Parvum
MIC (ug/mL)AzithromycinDoxycyclineMoxifloxacin
Minimum Inhibitory Concentrations (MIC) of U. Parvum0.5 (0.125 to 2.00)0.25 (0.125 to 0.50)0.25 (0.125 to 0.50)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Azithromycin + Placebo Doxycycline—1/304 (0.3%)53/304 (17.4%)
Active Doxycycline + Placebo Azithromycin—3/302 (1%)56/302 (18.5%)
Most frequent serious events
Most frequent serious events
EventActive Azithromycin + Placebo DoxycyclineActive Doxycycline + Placebo Azithromycin
Gun shot woundInjury, poisoning and procedural complications0/3041/302
Broken legInjury, poisoning and procedural complications0/3041/302
Optic neuritisEye disorders0/3041/302
Unstable mental statusPsychiatric disorders1/3040/302
Most frequent other events
Most frequent other events
EventActive Azithromycin + Placebo DoxycyclineActive Doxycycline + Placebo Azithromycin
NauseaGastrointestinal disorders28/30436/302
DiarrheaGastrointestinal disorders31/30435/302
OtherGastrointestinal disorders12/30417/302
VomitingGeneral disorders6/3047/302
RashGeneral disorders6/3047/302

Baseline characteristics

Age, Continuous
Age, Continuous(years)Active Azithromycin + Placebo DoxycyclineActive Doxycycline + Placebo AzithromycinTotal
Mean34.1 ± 9.833.3 ± 10.133.7 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Active Azithromycin + Placebo DoxycyclineActive Doxycycline + Placebo AzithromycinTotal
Female000
Male304302606
Region of Enrollment
Region of Enrollment(participants)Active Azithromycin + Placebo DoxycyclineActive Doxycycline + Placebo AzithromycinTotal
United States304302606
08

Study locations

1 site
  • Public Health -- Seattle & King County Sexually Transmitted Diseases Clinic located at Harborview Medical Center
    Seattle, Washington 98104, United States
09

References and documents

Publications

  • Khosropour CM, Manhart LE, Gillespie CW, Lowens MS, Golden MR, Jensen NL, Kenny GE, Totten PA. Efficacy of standard therapies against Ureaplasma species and persistence among men with non-gonococcal urethritis enrolled in a randomised controlled trial. Sex Transm Infect. 2015 Aug;91(5):308-13. doi: 10.1136/sextrans-2014-051859. Epub 2015 Jan 23. PubMed 25616607 ↗
  • Khosropour CM, Manhart LE, Colombara DV, Gillespie CW, Lowens MS, Totten PA, Golden MR, Simoni J. Suboptimal adherence to doxycycline and treatment outcomes among men with non-gonococcal urethritis: a prospective cohort study. Sex Transm Infect. 2014 Feb;90(1):3-7. doi: 10.1136/sextrans-2013-051174. Epub 2013 Oct 8. PubMed 24106340 ↗
  • Manhart LE, Gillespie CW, Lowens MS, Khosropour CM, Colombara DV, Golden MR, Hakhu NR, Thomas KK, Hughes JP, Jensen NL, Totten PA. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. Clin Infect Dis. 2013 Apr;56(7):934-42. doi: 10.1093/cid/cis1022. Epub 2012 Dec 7. PubMed 23223595 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2006
First posted
Jul 31, 2006
Start
Jan 2007
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results first posted
Mar 8, 2013
Last update
Aug 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00358462
Responsible party
Lisa Manhart (Study Principal Investigator, University of Washington) — Principal investigator
First posted
Jul 31, 2006
Start date
Jan 2007
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Mar 8, 2013
Last update
Aug 15, 2018

Study contacts

Lisa E Manhart, PhD
principal investigator · University of Washington

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azithromycin · Doxycycline

Start the discussion